02nd week of 2014 patent applcation highlights part 19 |
Patent application number | Title | Published |
20140010764 | GLYCATED MILK AND USES THEREOF - Milk-based products and drinks are provided including specified forms of identified proteins or fragments thereof, as are methods for the use of such milk-based products and drinks in the promotion of sleep. | 2014-01-09 |
20140010765 | MICRONUTRIENT SUPPLEMENT DISPENSING PACKAGE - Provided herein is a prenatal and postpartum multivitamin and mineral supplement package provided in the form of a plurality of solid oral dosage units individually contained in blister packs wherein a portion of the dosage forms are iron-containing while at least half of the dosage units are essentially iron-free and wherein the total amount of iron in the package as sold to purchasers is less than about 1300 mg of elemental iron. | 2014-01-09 |
20140010768 | FLAVORING INGREDIENT IN ORAL COMPOSITIONS - An oral composition containing an essential oil that provides a physical warming sensation when administered to the oral cavity and a method for achieving a physical warming sensation by administering the oral composition. The essential oil is rich in cis and trans-Piperitone Oxide and Piperitenone Oxide that impart unique organoleptic characteristics when the essential oil is used as the primary flavoring ingredient or as an additive in flavor compositions for chewing gum, confections, oral care applications, beverages, and general food applications. | 2014-01-09 |
20140010769 | COLOR CORRECTING COMPOSITIONS AND METHODS OF USE THEREOF - Compositions and methods of for changing the color of skin or body are described. | 2014-01-09 |
20140010772 | Highly Lustrous Silver-Colored Pigments with High Opacity and Metallic Appearance, Process for the Preparation Thereof and Use of Same - A silver-colored pigment is provided having a nonmetallic platelet-shaped substrate and at least one ilmenite-containing coating, wherein the nonmetallic platelet-shaped substrate is a nonmetallic platelet-shaped synthetic substrate and the amount of iron compounds, calculated as elemental iron, in the pigment is less than 5.0% by weight, based on the total weight of the pigment. Processes for preparing the pigment also are provided. | 2014-01-09 |
20140010773 | USE OF N-(4-METHOXYPHENYL)-1-PHENYL-1H-PYRAZOL-3-AMINE AND RELATED COMPOUNDS - This invention provides methods for treating diseases or conditions wherein the inhibition of Kit protein kinase may be beneficial, using pharmaceutical or cosmetic compositions comprising N-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-3-amine (FPL-62064) and related compounds. This invention also relates to the treatment of skin disorders, such as hyperpigmentation and cutaneous mastocytosis, and to cosmetic uses such as skin lightening. | 2014-01-09 |
20140010774 | SAFFRON ODORANTS - The present invention concerns a compound of formula (I), in the form of any one of its stereoisomers or a mixture thereof, and wherein the dotted line represents a carbon-carbon single or double bond; as well as its use as perfuming ingredient. | 2014-01-09 |
20140010775 | Solid Cosmetic Materials - To provide a solid makeup cosmetic material which has a high moisturizing effect, is superior in stability in a humidified environment and allows the moisturizing effect to be actually sensed upon use. In a solid makeup cosmetic material, 33% by mass or more of an oil component and 3 to 15% by mass of a moisturizing agent are incorporated with respect to the total amount of the cosmetic material. | 2014-01-09 |
20140010776 | POLYURETHANE UREA MIXTURE FOR HAIR COSMETICS - The invention relates to a specific polyurethane urea, which can be obtained by reacting a single polyisocyanate component, at least one polymeric polyol component, at least one hydrophilizing component and a single amino-functional chain extender component, wherein the polyisocyanate component comprises more than 75 mol % isophorone diisocyanate and the amino-functional chain extender component comprises more than 75 mol % isophorone diamine. Said polyurethane urea can be used in the field of hair cosmetics, in particular in the form of a mixture with conventional solvents. The invention further relates to the use of the polyurethane urea in cosmetics, to a cosmetic composition containing the polyurethane urea, to the use of the cosmetic composition in cosmetics, and to a method for forming hair styles using the cosmetic composition. | 2014-01-09 |
20140010777 | METHODS FOR DETERMINING PERSONALIZED TREATMENT COMPOSITIONS FOR PROSTATE CANCER AND BREAST CANCER - The present disclosure provides methods for selecting a treatment composition, or therapy, for the treatment of a cancer, such as prostate or breast cancer, in a patient wherein the treatment composition includes administering a combination of at least two components selected from two different classes of compounds. Methods for treating a patient using the selected treatment composition are also provided, together with methods for monitoring the efficacy of the treatment composition during a treatment period. | 2014-01-09 |
20140010780 | VACCINE IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS - A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naive T-cells and exposing the naive T-cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T-cells to gain immunization of the T-cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions. | 2014-01-09 |
20140010781 | SIRNA AGAINST CBL-B AND OPTIONALLY IL-2 AND IL-12 FOR USE IN THE TREATMENT OF CANCER - The invention relates to a method for the immune activation of NK cells by the reduction or inhibition of the Cbl-b function in said cells. This stimulates the congenital immune system and thus permits the therapy of appropriate diseases. | 2014-01-09 |
20140010782 | ANTIBACTERIAL AGENT FOR TREATING INFECTIOUS DISEASES OF BACTERIAL ORIGIN - The invention relates to medicine, namely to the antimicrobial agent for the treatment of infectious bacterial diseases including hospital infections and drug-resistant TB which represents the ion nanostructured complex (INSC) synthesized from carbohydrates proteins and/or polypeptides (albumins, interleukins, interferons, signaling proteins, etc), which are to enhance the antimicrobial activity in vivo, by activating immune cells that contain at least one terminal amino acid such as Phe, Ala, Val, Ala, Leu, Ile, and others with electron-donor functional groups, iodine and halides of the alkali and alkaline earth elements in the fourth stage at a certain ionic strength; an antibacterial agent increases: the susceptibility of bacteria, including antibiotic-resistant, to antibiotics; activity of monocytes and macrophages; efficiency of antibiotic treatment of hospital infections and drug-resistant TB; it also has antiviral activity, stimulates hematopoietic function of bone marrow; has an antitumor effect and radioprotective properties; in acceptable concentrations of components can be used as non-pharmaceutical agent (BAFS or parapharmaceutical); is presented in the pharmacological form suitable for parenteral, oral, external, or other application. INSC has the formula [{(Ln(MeI3)+)y[Me(Lm)I]+x}(Cl—)y+x+k] with M=30-300 kDa. | 2014-01-09 |
20140010783 | ANTIVIRAL COMPOUNDS - The present invention discloses compounds of Formula I: | 2014-01-09 |
20140010784 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE - The present invention relates to peptidomimetic compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. | 2014-01-09 |
20140010785 | Methods for Use of a Specific Anti-Angiogenic Adenoviral Agent - Anti-angiogenic adenovirus vectors, and therapeutic use thereof are provided, and more particularly, but not exclusively, clinical protocols for treatment of solid tumors in patients with an Ad5-PPE-1-3X-fas-chimera adenovirus vector. | 2014-01-09 |
20140010790 | CELL CULTURE MATERIAL BASED ON MICROBIAL CELLULOSE - The present invention relates material based on microbial cellulose that is useful in culturing and transferring cells as well as delivering drugs. The material comprises cellulose nanofibers and/or derivatives thereof, based on microbial cellulose, wherein the cellulose nanofibers are in a form of a hydrogel or membrane. The invention also provides methods for producing these materials and compositions and uses thereof. | 2014-01-09 |
20140010791 | METHODS FOR REGULATING PROTEIN FUNCTION IN CELLS IN VIVO USING SYNTHETIC SMALL MOLECULES - Methods and compositions for the rapid and reversible destabilizing of specific proteins in vivo using cell-permeable, synthetic molecules are described. | 2014-01-09 |
20140010794 | Formulation and Method for Preparing Specific T Cell, and Method for Preparing the Formulation - The present invention provides a formulation and method for preparing specific T cells, and a method for fabricating the above formulation is also disclosed. The formulation can induce specific T cell responses and comprises at least a cell population of dendritic killer cells presenting specific antigens. In addition, the method mentioned above for preparing specific T cells comprises following steps. A cell population of T cells is provided at first. And then, a formulation of preparing specific T cells is added to mix with the cell population of T cells. After cultivating, the specific T cells are harvested. Furthermore, the method for fabricating the above formulation comprises the following steps. First, a cell population of dendritic killer cells is provided. A target sample is then provided, and a step of making the cell population of the dendritic killer cells co-cultivate with the target sample is performed. After co-cultivating, a cell population of dendritic killer cells presenting specific antigens is harvested. | 2014-01-09 |
20140010795 | FORMULATION AND METHOD FOR THE PREVENTION AND TREATMENT OF BONE METASTASES OR OTHER BONE DISEASES - A suspension of erythrocytes encapsulating a bisphosphonate is provided along with a method for its use for the prevention and treatment of bone metastases and other bone marrow diseases. The suspension of erythrocytes encapsulating a bisphosphonate may also be provided in which the erythrocytes have undergone a chemical treatment with an agent such as BS3 so as to promote targeting of the bone marrow. The method for the prevention and treatment of bone metastases may be accomplished by administering to a patient in need thereof of a suspension of erythrocytes encapsulating a second-generation or a third-generation bisphosphonate. | 2014-01-09 |
20140010796 | Application Methods to Rapidly Alter Disease and Injury States Using Molecular Transport of B6 - The present invention discloses methods of application employing B51B6 vitamins in molecular transport creams or gels to deliver B6 in a high dose to bring about therapeutic ways in human or mammal tissues to reverse a disease process or injury to bring about normal function of the affected tissues. Examples of disease changes to normal include, but are not limited to strokes, cellulitis, facial acne, precancerous lesions, nerve injury like paresthesia, periorbital hematoma, pentathol general anesthesia recovery, headaches, improved sight, hypothyroidism, dental pain, dental gingivitis, insect bites, delayed hypersensitivity states, phlebitis of veins and synergism of steroid activity. | 2014-01-09 |
20140010797 | Fusion Molecules of Rationally-Designed DNA-Binding Proteins and Effector Domains - Targeted transcriptional effectors (transcription activators and transcription repressors) derived from meganucleases are described. Also described are nucleic acids encoding same, and methods of using same to regulate gene expression. The targeted transcriptional effectors can comprise (i) a meganuclease DNA-binding domain lacking endonuclease cleavage activity that binds to a target recognition site; and (ii) a transcription effector domain. | 2014-01-09 |
20140010798 | ALBUMIN FUSION PROTEINS - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention. | 2014-01-09 |
20140010799 | HUMAN DIACYLGLYCEROL ACYLTRANSFERASE 2 (DGAT2) FAMILY MEMBERS AND USES THEREFOR - The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed. | 2014-01-09 |
20140010802 | SYSTEMS AND METHODS FOR DIAGNOSING A PREDISPOSITION TO DEVELOP CANCER - Systems, methods, and computer readable media for diagnosing or characterizing a genetic predisposition to develop cancer, including cancers of the BAP1 cancer syndrome, are provided. Nucleic acids comprising a germline nucleic acid sequence encoding the BRCA1 associated protein 1 (BAP1) are sequenced or probed to determine if the nucleic acid sequence includes alterations that predispose a subject to develop cancer. | 2014-01-09 |
20140010803 | HIGH FREQUENCY APPLICATION OF BOTULINUM TOXIN THERAPY - The present invention relates to methods for treating diseases and disorders by administering a composition containing the neurotoxic component of a | 2014-01-09 |
20140010806 | Treatment of Ocular Diseases - The invention relates to methods to use 17α-ethynylandrost-5-ene-3β,7β,17β-triol to treat ocular diseases or conditions such as dry eye, uveitis or retinitis. The compound can be administered topically to the eye, by intravitreal injection or systemically, e.g., orally. | 2014-01-09 |
20140010807 | NOVEL COMPOUNDS - The present invention relates to an antibody which has multiple specificities. In particular the antibody of the present invention binds to (cross react with) human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78. | 2014-01-09 |
20140010808 | ANTI CD37 ANTIBODIES - Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology. | 2014-01-09 |
20140010809 | BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS - The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high express levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins. | 2014-01-09 |
20140010810 | Anti-Jagged 1/Jagged 2 Cross-Reactive Antibodies, Activatable Anti-Jagged Antibodies And Methods Of Use Thereof - This invention relates generally to the generation of antibodies, e.g., monoclonal antibodies including fully human monoclonal antibodies, that recognize Jagged 1 and/or Jagged 2, to antibodies, e.g., monoclonal antibodies including fully human antibodies that recognize Jagged 1 and/or Jagged 2, and nucleic acid molecules that encode antibodies, e.g., nucleic acid molecules that encode monoclonal antibodies including fully human cross-reactive antibodies that recognize both Jagged 1 and Jagged 2, and to methods of making the anti-Jagged antibodies and methods of using the anti-Jagged antibodies as therapeutics, prophylactics, and diagnostics. The invention also relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically bind to Jagged 1 and Jagged 2, and to methods of making and using these activatable anti-Jagged antibodies in a variety of therapeutic, diagnostic and prophylactic indications. | 2014-01-09 |
20140010811 | ANTIBODIES TO ENDOPLASMIN AND THEIR USE - Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma. | 2014-01-09 |
20140010812 | MODULATING AGONISTIC TNFR ANTIBODIES - The instant invention relates to agents (e.g., agonistic antibodies) able to stimulate the immune system of a mammalian animal and activate target-cell specific T lymphocyte responses. Such agents may be identified based on the ability to engage a receptor from the TNFR Superfamily and thereby mimic the natural ligand for the receptor from the TNFR Superfamily. Modified antibodies of this class display enhanced immunostimulatory activity and may be formulated and administered for the treatment of a disease or disorder. | 2014-01-09 |
20140010813 | B-CELL REDUCTION USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES - The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules. | 2014-01-09 |
20140010816 | TREATMENT AND PREVENTION OF MALARIA - The present invention relates to polypeptides from | 2014-01-09 |
20140010817 | Novel Antibodies and Uses Thereof - The present invention provides an antibody that recognizes a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 15 in the Sequence Listing and has an anti-arthritic function, or a functional fragment thereof. | 2014-01-09 |
20140010826 | Use of DR6 and p75 Antagonists to Promote Survival of Cells of the Nervous System - The present invention relates to Death Receptor-6 (DR6) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to be important for regulating apoptosis in cells of the nervous system. In addition, it has been discovered that p75 is a ligand for DR6. As a result, this invention relates to methods for inhibiting the interaction of DR6 and p75 using DR6 and/or p75 antagonists. In addition, the methods described herein include methods of promoting survival of cells of the nervous system using DR6 antagonists, optionally in combination with p75 antagonists, and methods of treating neurodegenerative conditions by the administration of a DR6 antagonists, optionally in combination with a p75 antagonist. | 2014-01-09 |
20140010827 | ANTIBODY FORMULATIONS - Formulations of anti-VLA-1 antibodies are described. | 2014-01-09 |
20140010830 | Non-Coding Immunomodulatory DNA Construct - The present invention relates to a nucleic acid molecule and its use for the modulation of the immune system. It provides a DNA construct for immunomodulation comprising at least one nucleotide in L-conformation. | 2014-01-09 |
20140010831 | HER-2 PEPTIDES - Compositions, methods, and vaccines that may stimulate the immune system and that may be used for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include epitopes of the HER-2 proteins. | 2014-01-09 |
20140010834 | NON-PATHOGENIC SEROTYPE 4 FOWL ADENOVIRUS (FADV-4) AND VIRAL VECTOR THEREOF - A high level replication fowl adenovirus (FAdV) isolate capable of reaching a viral titer of at least 3 log 10 is described. Said FAdV is a non-pathogenic strain of fowl adenovirus serotype 4, identified as FAdV-4 ON1. Additionally, the present disclosure also provides a viral vector comprising the fowl adenovirus, which has inserted an exogenous nucleotide sequence coding for at least one antigenic site of a disease of concern, as well as a method for obtaining said viral vector and an immunogenic composition comprising the same. | 2014-01-09 |
20140010835 | MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETO - The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a | 2014-01-09 |
20140010836 | ANTIGENIC GLY1 POLYPEPTIDES - We disclose antigenic polypeptides that induce the production of opsonins, in particular opsonic antibodies, and the use of said antigenic polypeptides in vaccines that are protective against bacterial animal pathogens in particular bacterial pathogens of agriculturally important animal species and companion animals and including zoonotic Gram negative bacterial species. | 2014-01-09 |
20140010837 | Methods and Compositions for Preventing a Condition - Provided herein are methods, compositions, and kits for preventing, inhibiting, reducing the severity of, or treating a disease or condition. A pharmaceutical composition provided herein can comprise a nucleic acid sequence encoding an antigen fused to an immune cell product, e.g., MIP-3α, and an adjuvant. The antigen can be from a bacteria, virus, fungus, parasite, or cancer. The antigen can be an Alzheimer's disease antigen. | 2014-01-09 |
20140010838 | Extracts of Microalgae and Their Application - Suggested are new extracts of microalgae selected from the group consisting of (i) | 2014-01-09 |
20140010839 | METHOD OF SCREENING ANTIRETROVIRAL COMPOUNDS AND VACCINE - The present invention relates to an in vitro method of screening for candidate compounds capable of being used for the preventative and/or curative treatment of a disease caused by a retrovirus in which the candidate compound which modulates the expression and/or the activity of the SAMHD1 protein is identified as a candidate compound capable of being used for the preventative and/or curative treatment of a disease caused by a retrovirus. | 2014-01-09 |
20140010840 | RECOMBINANT MUMPS VIRUS VACCINE - The present invention provides the complete genomic sequence of the epidemic mumps virus (MuV) strain MuV | 2014-01-09 |
20140010841 | Attenuated Recombinant Alphaviruses Incapable of Replicating in Mosquitoes and Uses Thereof - The present invention discloses an attenuated recombinant alphavirus that is incapable of replicating in mosquito cells and of transmission by mosquito vectors. These attenuated alphavirus may include but is not limited to Western Equine Encephalitis virus, Eastern equine encephalitis virus, Venezuelan equine encephalitis virus or Chikungunya virus. The present invention also discloses the method of generating such alphaviruses and their use as immunogenic compositions. | 2014-01-09 |
20140010842 | METHOD FOR MODULATING A BACTERIAL INVASION SWITCH - The subject matter disclosed herein pertains to the modulation of a bacterial invasion switch and the subsequent use of the bacterium to vaccinate an organism. In one embodiment, the bacterial invasion switch is modulated by changing the proteolysis of ExoR protein. In another embodiment, a mutated bacterium produces a mutant ExoR protein that resists proteolysis. | 2014-01-09 |
20140010843 | METHOD OF DETOXIFICATION - The present invention relates to a method of detoxifying bacterial cytolysins such as pneumococcal pneumolysin, utilizing chemical cross-linking compounds. | 2014-01-09 |
20140010844 | Tissue Targeted Antigenic Activation of the Immune Response to Treat Cancers - The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. The formulations of the invention thereby facilitate activation of an immune response to a cancer in a particular tissue or organ. The compositions may for example include killed or attenuated microbial pathogens, such as whole killed bacterial cells, and may be administered at sites distant from the cancer, for example the skin. In some embodiments, microbial species of endogenous flora that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions. In alternative embodiments, exogenous microbial pathogens that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions. The administration of the immunogenic compositions may be repeated relatively frequently over a relatively long period of time. In embodiments for intradermal or subcutaneous injection, dosages may be adjusted so that injections reproduce a consistent, visible, delayed inflammatory immune reaction at the successive site or sites of administration. | 2014-01-09 |
20140010845 | SUPPRESSION OF A HYPERSENSITIVITY IMMUNE RESPONSE WITH UNRELATED ANTIGEN DERIVED FROM ALLERGEN SOURCE MATERIAL - The present invention relates to the treatment of a hypersensitivity immune response, such as allergic rhinitis or asthma, via bystander suppression by use of an antigen unrelated to the allergen triggering the hypersensitivity immune response in an individual to be treated, wherein the antigen is obtainable from the source material comprising the “triggering” allergen. | 2014-01-09 |
20140010848 | GAS-FILLED MICROBUBBLES AND SYSTEMS FOR GAS DELIVERY - Compressible and concentrated suspensions containing gas-filled microbubbles, uses thereof for delivering gas into a subject in need thereof, and systems for delivering the compressible suspensions. The gas-filled microbubbles each comprise a gas core surrounded by a lipid membrane, which includes (a) one or more lipids, such as 1,2-disteroyl-sn-glycero-3-phosphocholine (DSPC) or dipalmitoylphosphatidylcholine (DPPC), and (b) one or more stabilizing detergents, such as poloxamer 188, Pluronic F108, Pluronic F127, polyoxyethylene (100) stearyl ether, cholesterol, gelatin, polyvinylpyrrolidone (PVP), and sodium deoxycholate (NaDoc). | 2014-01-09 |
20140010849 | PEANUT ALLERGY TREATMENT - The present invention provides compositions, systems, and methods for preventing and treating allergic reactions to peanut exposure. In certain embodiments, the present invention employs fusion proteins comprising a peanut allergen (or allergenic portion thereof), such as Ara h2, and an Fc protein (e.g., Fcγ1 protein), or functional portion thereof. | 2014-01-09 |
20140010850 | ALBUMIN FIBERS AND FABRICS AND METHODS OF GENERATING AND USING SAME - Provided are method of generating a fiber from a globular protein such as albumin. Also provided are albumin fibers and fabrics and methods of using same for bonding a damaged tissue or for ex vivo or in vivo formation of a tissue. | 2014-01-09 |
20140010851 | PATCH FOR ORAL HEALTH CARE - The present invention is directed to a U-shaped patch for oral health care, comprising a thin film layer and a support layer, and the inner and outer margin of the U-shaped patch have at least one notch or cut line so that the patch can be folded as a three-dimensional concave shape, wherein the thin film layer comprises a health care agent. The present invention uses a two-layered design comprising a thin film layer and a support layer, and a health care agent in the adhesive layer effective for caries prevention, whitening and/or remineralization. The patch of the present invention can closely cover teeth with the thin film layer to enable the health care agent to tightly contact the teeth so as to increase the efficacy on tooth care. | 2014-01-09 |
20140010856 | MATERIALS WITH MODIFIED SURFACES AND METHODS OF MANUFACTURING - Various embodiments of surface-modified devices, components, and associated methods of manufacturing are described herein. In one embodiment, an implantable device suitable for being implanted in a patient includes an implantable material having a utile shape and a surface and a modification material deposited on at least a portion of the surface of the implantable material. The modification material has a release rate in an implantation environment in the patient. The modification material at the release rate is effective as bactericidal without being cytotoxic to the patient. | 2014-01-09 |
20140010857 | Cell Preparations For Extemporaneous Use, Useful for Healing and Rejuvenation In Vivo - The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell combinasons preparations for use in tissue regeneration and bone regeneration and pain reduction. | 2014-01-09 |
20140010861 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE - The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | 2014-01-09 |
20140010862 | MULTIFUNCTIONAL BIODEGRADABLE PEG NANOCARRIER-BASED HYDROGELS FOR PREVENTING HIV TRANSMISSION - A multifunctional polyethylene glycol-based hydrogel that includes a multi-arm polyethylene glycol cross-linking unit covalently bound to at least four multi-arm polyethylene glycol nanocarrier units, wherein each nanocarrier unit includes an agent coupled to the nanocarrier unit and each agent is selected from pH-lowering agents, bioadhesion agents, microbicidal-spermicidal agents, and agents that inhibit free and cell-associated HIV binding, provided that each nanocarrier unit comprises a different agent. | 2014-01-09 |
20140010863 | LIPOSOMES FOR PROTECTION AGAINST TOXIC COMPOUNDS - Methods of preparing a proteoliposome comprise the step of contacting a liposome with an effective portion of RalBP1 to create a proteoliposome. RalBP1 is effective for the protection and treatment of mammals and the environment against the accumulation of toxic compounds and prevents accumulation of one or more toxic compounds, reduces the concentration of toxic compounds, and protects against further contamination with one or more toxic compounds. | 2014-01-09 |
20140010868 | KRILL OIL AND CAROTENOID COMPOSITION, ASSOCIATED METHOD AND DELIVERY SYSTEM - A medicine delivery system includes an inner capsule containing carotenoids and an outer capsule in which the inner capsule is contained within the outer capsule and the outer capsule containing a therapeutically effective amount of krill oil. In one example, the carotenoids comprise at least S,S′-astaxanthin derived from | 2014-01-09 |
20140010869 | FORMULATION AND MANUFACTURING PROCESS FOR CALCIUM ACETATE CAPSULES - The present invention relates to a pharmaceutical calcium acetate formulation and a process for making the same. In particular, the present invention relates to a calcium acetate capsule formulation comprising granules comprising calcium acetate along with other formulation adjuvants contained within a pharmaceutically acceptable capsule. | 2014-01-09 |
20140010870 | PHARMACEUTICAL FORMULATION COMPRISING INOSITOL - The present invention relates to a pharmaceutical composition comprising solutions, suspensions of dispersions of inositol, or an isomer thereof, in a vehicle comprising gelatin, glycerol or mixtures thereof. | 2014-01-09 |
20140010871 | METHODS AND COMPOSITIONS FOR TREATMENT OF URINIARY TRACT INFECTIONS - A composition for treatment of urinary tract infection derived primarily from pomegranate and cranberry fruit components is disclosed. The composition may be derived from juices, concentrates, liquid extracts, or powdered extracts, e.g. dehydrated pomegranate juice, of pomegranate and cranberry fruits. The concentration of each of the component (i.e. pomegranate product and cranberry product) in the composition is set such as to achieve optimum synergistic effects by increasing urinary tract anti-adhesion activity. | 2014-01-09 |
20140010872 | ORAL COMPLEX COMPOSITION COMPRISING OMEGA-3 FATTY ACID ESTER AND HMG-COA REDUCTASE INHIBITOR - An oral complex composition comprising omega-3 fatty acid esters and HMG-CoA reductase inhibitor, can effectively raise serum HDL level while reducing serum LDL and TG levels and can be used to treat hyperlipidemia owing to its good drug dissolution rate and storage stability with showing no delayed release behavior even after 6 months of accelerated storage. | 2014-01-09 |
20140010876 | PHARMACEUTICAL ADMINISTRATION FORMS COMPRISING 5-CHLORO-N-(METHYL)-2-THIOPHENECARBOXAMIDE - The present invention relates to solid orally administrable pharmaceutical administration forms comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide (rivaroxaban, active compound (I)), wherein a partial amount of the active compound (I) is released rapidly and a partial amount is released in a controlled manner (modified, retarded, delayed), and to processes for their preparation, their use as medicaments and their use for the prophylaxis, secondary prophylaxis or treatment of disorders. | 2014-01-09 |
20140010877 | PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF - The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts. | 2014-01-09 |
20140010880 | Tricalcium Phosphate Coarse Particle Compositions and Methods for Making the Same - Methods for preparing a tricalcium phosphate coarse particle composition are provided. Aspects of the methods include converting an initial tricalcium phosphate particulate composition to hydroxyapatite, sintering the resultant hydroxyapatite to produce a second tricalcium phosphate composition and then mechanically manipulating the second tricalcium phosphate composition to produce a tricalcium phosphate coarse particle composition. The subject methods and compositions produced thereby find use in a variety of applications. | 2014-01-09 |
20140010881 | LOW SURFACTANT IODINE TOPICAL DISINFECTANT - Iodine-containing germicidal compositions are disclosed that remain physically stable for extended storage periods with little to no iodine complexing agent being present. The compositions employ a mixture of emollients, such as glycerin and ethoxylanolin, to create a composition that in certain embodiments presents a cloudy or emulsion-like appearance. | 2014-01-09 |
20140010884 | DERMATOLOGICAL COMPOSITIONS COMPRISING RETINOIDS, DISPERSED BENZOYL PEROXIDE AND CARRAGEENANS - Dermatological compositions containing, in a physiologically acceptable medium, at least one retinoid, dispersed benzoyl peroxide and at least one gelling agent of the family of the carrageenans, are useful for treating dermatological conditions and afflictions linked to disorders of cell differentiation and/or proliferation and/or keratinization, notably for treating acne vulgaris. | 2014-01-09 |
20140010885 | SELF-ASSEMBLING NANOPARTICLE DRUG DELIVERY SYSTEM - A self-assembling nanoparticle drug delivery system for the delivery of various bioactive agents including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the bioactive agent, a lipid layer or lipid/cholesterol layer coat and targeting or facilitating molecules anchored in the lipid layer. A method for construction of the self-assembling nanoparticle drug delivery system is also provided. | 2014-01-09 |
20140010894 | SUSTAINED RELEASE BEADS AND SUSPENSIONS INCLUDING THE SAME FOR SUSTAINED DELIVERY OF ACTIVE INGREDIENTS - Sustained-released beads providing active ingredients over an extended period of time to an individual orally ingesting the sustained release beads. The sustained-release beads can be part of a suspension wherein the sustained-release beads are suspended and evenly dispersed in the suspension. Binding agents are used to form the structural framework of the sustained released beads and retain the active ingredients without chemical or electrical bonding. The components of the dispersion medium are GRAS designated, making the suspension suitable for use as a food product. | 2014-01-09 |
20140010895 | COLONOSCOPY - PREPARATION - The invention provides a colon cleansing solution comprising: a) 300 to 2000 mmol per litre ascorbate anion provided by ascorbic acid, one or more salts of ascorbic acid, or a mixture thereof; and b) 10 to 200 g per litre polyethylene glycol. The invention also provides methods and kits associated with, or making use of the solutions. The invention also provides a method of cleansing the colon of a subject comprising: — administering to the subject an effective amount of a first cleansing solution; and then after a time interval-administering to the subject an effective amount of a second cleansing solution, where in the two cleansing solutions are as described in the specification. | 2014-01-09 |
20140010896 | Composition for removing a tick and providing relief - In an embodiment of the present invention, a composition for removing a tick and providing relief therefrom comprises a solvent, a carrier fluid suitable for increasing the rate of seepage of the solvent into the host, a solubilizer suitable for increasing the solubility of the composition in water, and a solution that provides soothing and aids in healing the host. | 2014-01-09 |
20140010897 | New positive allosteric modulators of nicotinic acetylcholine receptor - The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor. | 2014-01-09 |
20140010908 | METHOD FOR MANUFACTURING THREE-DIMENSIONAL SHAPED OBJECT AND THREE-DIMENSIONAL SHAPED OBJECT - There is provided a method for manufacturing a three-dimensional shaped object, comprising the steps of: (i) forming a solidified layer by irradiating a predetermined portion of a powder layer with a light beam, thereby allowing sintering of the powder of the predetermined portion or melting and subsequent solidification thereof; and (ii) forming another solidified layer by newly forming a powder layer on the resulting solidified layer, and then irradiating another predetermined portion of the new powder layer with the light beam, the steps (i) and (ii) being repeatedly performed, wherein the three-dimensional shaped object is manufactured such that it has three different solidified portions of high-density, intermediate-density and low-density solidified portions in at least a part of the object, and wherein the intermediate-density solidified portion is formed to be located in a part of a surface of the three-dimensional shaped object. | 2014-01-09 |
20140010909 | MOLD STACK FOR A PREFORM - There is provided a molding stack assembly ( | 2014-01-09 |
20140010910 | BLOW MOULD - A blow mould for containers wherein the mould base comprises a first member ( | 2014-01-09 |
20140010911 | SWEEP CORE DIE DEVICE - A sweep core die device for a throttle body, or other part, has a cover insert and an ej insert that engage leaving voids therein, a ram component entering the voids, and cores connected to the ram component by ball joints and other components for simultaneous movement in several axes within the voids. The cores are mirror image and connect to one end of a mount. The other end of the mount pivotally connects to the ej insert. A shaft pivotally connects to each mount and to a clamp outwardly from the inserts. The clamp moves relative to the two inserts, moves the shafts, and thus rotates the cores inwardly and outwardly through the voids. The cores have the internal shape of the passage through each horn of a finished throttle body or other part. The cores produce passages so fuel attains laminar flow within the part. | 2014-01-09 |
20140010912 | LOW CALORIE INFANT FORMULA WITH IMPROVED PHYSICAL ATTRIBUTES - The present disclosure is directed to low calorie infant formulas, and in particular, low calorie infant formulas that have a low buffering capacity, exhibit an increased rate of protein hydrolysis and digestion, and have an improved tolerance, as compared to full calorie infant formulas. Also disclosed are low calorie liquid infant formulas that have a reduced (i.e., “low”) micronutrient content on a per volume basis, and exhibit an overall improvement in the physical properties of the formula, as compared to low calorie liquid infant formulas having a higher micronutrient content. | 2014-01-09 |
20140010913 | TOLERANCE IN A LOW CALORIE INFANT FORMULA - The present disclosure is directed to low calorie infant formulas, and in particular, low calorie infant formulas that have a low buffering capacity, exhibit an increased rate of protein hydrolysis and digestion, and have an improved tolerance, as compared to full calorie infant formulas. Also disclosed are low calorie liquid infant formulas that have a reduced (i.e., “low”) micronutrient content on a per volume basis, and exhibit an overall improvement in the physical properties of the formula, as compared to low calorie liquid infant formulas having a higher micronutrient content. | 2014-01-09 |
20140010916 | FOOD ANALOGS AND METHODS FOR MAKING FOOD ANALOGS - The invention provides food analogs and methods of making the food analogs. In general, the methods comprise comminuting one or more meats to produce a meat slurry, admixing one or more flours to produce a powder blend, admixing the meat slurry and the powder blend to produce a dough, and extruding the dough at a shear mechanical energy ranging from about 50 kJ/kg to about 500 kJ/kg and at a temperature ranging from about 60° C. to about 120° C. to produce a food analog. Colorant can be added before, during, or after the admixing or extrusion processes to provide a more natural appearance to the food analog. The food analog can be a meat analog having the appearance of a meat or a non-meat food analog such as a fruit or vegetable. | 2014-01-09 |
20140010917 | GLUCOSYLATED STEVIOL GLYCOSIDES COMPOSITION AS A TASTE AND FLAVOR ENHANCER - A taste and flavor profile enhancing composition is described. The composition includes glucosylated steviol glycosides which can enhance the intensity of a taste and/or a flavor in a food or beverage product. | 2014-01-09 |
20140010922 | Electrostatic Activation of Vaporized Fluids - Methods previously shown to be effective in imparting a prolonged, non-temperature-related, increase in an intrinsic energy of fluids, including water and ethanol, have been applied to heat generated vapors of these fluids, leading to effective activation of the fluids upon their condensation. In a specific embodiment, a Van de Graaf generator was used to apply an electrostatic field to the vapors. The condensed fluids from these electrostatically activated vapors display enhanced internal mobility, more dynamic solubillization patterns using of sprinkled particles of neutral red dye and a progressive, but limited, reduction in measured weight. Fluids condensing from electrostatically-energized vapors can also impart intrinsic energy to other fluids by simple dilution. The described methods are relevant to an understanding of homeopathy. | 2014-01-09 |
20140010923 | METHOD FOR FLAVORING CORN BEANS FOR POPCORN AND CORN BEAN PRODUCT OBTAINED BY SAID METHOD - The method comprises the steps of: i) applying a portion of adhesive liquid on the unpopped kernels, comprising said adhesive liquid an aqueous based adhesive composition; ii) after step i), applying a portion of flavorant on said kernels, keeping said kernels under movement at a temperature from 50° C. to 70° C. for enough time in order to allow the evaporation of water from said adhesive liquid, iii) cyclically repeating steps i) and ii) until each of said steps is carried out at least two times while said kernels are kept at a temperature from 50° C. to 70° C., the repetition of said steps I) and ii) allowing the formation of a coating film over the kernel, said coating film comprising a plurality of layers of adhesive and flavorant. The product is characterized in that said kernels comprise at least 4.5% by weight of flavorant with respect to the total weight of the unpopped kernel. It has been observed that the waste of flavorant is reduced very significantly, the application efficiency being very higher. | 2014-01-09 |
20140010926 | CAPSULE FOR MAKING BEVERAGES - A capsule ( | 2014-01-09 |
20140010927 | PACKAGING FOR FOOD PRODUCT - A packaged food product includes a food product; a packaging having an interior containing the food product, the packaging including a first film defining a recess to receive the food product, the first film having an anti-fog treatment applied to at least a portion of the recess, the first film configured to define a space between the food product and the first film and receive heated water vapor released from the food product during heating of the food product; and a second film releasably sealed to the first film, the second film comprising an absorbent layer configured to absorb moisture released from the food product; and at least one vent portion configured to relieve steam pressure from the interior during heating of the food product. | 2014-01-09 |
20140010932 | High pressure pasteurization of fresh sausage and fresh meat emulsion and avoiding the loss of color and taste in the process - A process of preserving fresh sausages or fresh meat emulsions with high pressure and avoiding color fading and diminishing of taste comprises the steps of a) packing the products into sealed packages, b) Putting the packages into a pressurization vessel, increasing pressure in the vessel up to 100.000 PSI that the packages are exposed to the elevated pressure. c) Maintaining pressure for a time up to 300 seconds, at a temperature up to 45 F, d) removing the packages with fresh meat products from the pressure vessel. Pathogens are killed during this process providing a longer shelf life while retaining taste, color compared to having fresh meat products that are packed without the benefit of high pressure. To avoid color fading and loss of flavor during this process, spices which are not part of the original and historical recipe are used to compensate. | 2014-01-09 |
20140010933 | Methods, Systems, and Devices for Improving Quality of Cherries Post-Harvest - Provided herein are methods, systems, and devices for improving the quality of fruit, for example, the quality of cherries. There are methods for improving shelf-life and methods for reducing splitting. The methods comprise applying a product or combination of products to the cherries post-harvest and prior to hydrocooling. Such products include sucrose ester based coatings, osmo-regulators, and/or antitranspirants. The systems for packing comprise: (a) picking cherries and placing the cherries into bins in the field; (b) applying a sucrose ester based coating, an osmo-regulator, or an antitranspirant to the cherries using a device configured to treat one or more cherry bins with a solution containing the sucrose ester based coating, an osmo-regulator, or an antitranspirant; (c) moving cherries through a hydrocooler; and (d) moving cherries into a warehouse and onto a packing line. | 2014-01-09 |
20140010934 | Hot Beverage Maker with Cup-Actuated Dispenser - A method for operating a hot beverage maker includes the steps of infusing fresh water and storing the resulting beverage in a removable brewed beverage tank. An actuator is engaged for dispensing the brewed beverage from the tank. The tank is placed on a platform in a relationship so as to engage a warmer plate to keep the contents of the tank warm. Accordingly, the hot beverage maker produces a brewed beverage that is stored in the tank until it is dispensed by a user. | 2014-01-09 |
20140010935 | DRIED PASTA MANUFACTURING METHOD - Provided is dried pasta having no or very little cracking and a manufacturing method therefor. The method for manufacturing dried pasta comprises a drying step of drying pasta noodle strands to reach the percentage of water content of 14% or less under an environment maintained at a temperature of 75 to 95° C. and humidity of 60 to 90%; a heating step of heating, after the drying step, the pasta noodle strands for 10 to 120 minutes under an environment maintained at a temperature lower by at least 15° C. than the temperature in the drying step and within a range of 50 to 80° C., and humidity of 60 to 90%; and a cooling step of cooling, after the heating step, the pasta noodle strands for 10 to 60 minutes under an environment maintained at a temperature of 20 to 40° C. and humidity of 40 to 80%. | 2014-01-09 |
20140010936 | SPOUT, SYSTEM, AND METHOD FOR PRODUCING A FOAM - A spout, system, and method for producing a foam from a pressurized mixture of a liquid containing gas bubbles, e.g., air bubbles. The spout consists of a spout enclosure defining the body of the spout, and which receives the pressurized mixture and conveys the foam out of the spout enclosure. The spout enclosure houses a plurality of screens disposed in series that successively screen the pressurized mixture. Each screen is separated from a consecutive screen by a screen spacing. The screening of the pressurized mixture progressively transforms the gas bubbles in the liquid into foam bubbles of a smaller and generally uniform size. The system uses a manifold having a plurality of intakes which introduce under pressure into a chamber gas, and a solute, solvent or liquid, thereby generating the pressurized mixture containing gas bubbles. This mixture is conveyed out of the chamber via an outtake to the spout enclosure. | 2014-01-09 |
20140010937 | MOIST AND CRISPY PRODUCT HOLDING CABINET WITH HEATED AIRFLOW - A food holding cabinet having at least one heating chamber for holding at least one food tray therein, the cabinet comprising: a housing that defines the heating chamber and a heating chamber opening for access to the heating chamber, wherein the heating chamber comprises an top portion, front portion, a rear portion, and at least one tray location for receiving a food tray; a jet plate including a plurality of apertures, the jet plate is disposed between the heating chamber and an upper plenum, wherein the upper plenum is formed between an upper surface of the jet plate and a lower surface of the top portion of the heating chamber; and a blower positioned to provide heated gas into the upper plenum, wherein the gas exits the upper plenum through the apertures into the heating chamber such that it is direct substantially toward the food tray. | 2014-01-09 |
20140010938 | METHOD AND APPARATUS FOR COOLING AND TRANSPORTING A BEVERAGE - A device for cooling and flavoring a beverage having a tube with a closed first end and an open second end. Between the first and second end is a plurality of openings. A cap is removably attached to the open end. A cover strip is attached to the cap and extends into the tube such that as the cap is rotated in relation to the tube, the cover strip selectively covers and uncovers the plurality of | 2014-01-09 |
20140010939 | Sweetness Enhancers, Sweetener Compositions, Methods of Making the Same and Consumables Containing the Same - The present invention relates to novel sweetness enhancer compounds of the formula (I), | 2014-01-09 |
20140010952 | PCB REPAIR OF DEFECTIVE INTERCONNECTS BY DEPOSITION OF CONDUCTIVE INK - There may be provided a system that may include a computer arranged to process images of areas of missing conductive material defects of an electrical circuit and to determine a defect correction scheme that defines a manner in which at least one of the missing conductive material defects should be amended; and
| 2014-01-09 |
20140010953 | SINTERING ADDITIVES FOR CERAMIC DEVICES OBTAINABLE IN A LOW pO2 ATMOSPHERE - The present invention provides a method for producing a ceramic device in a low pO | 2014-01-09 |
20140010954 | Power Line Rider Applicator Tool - A tool and method for assisting in the maintenance and inspection of power lines by providing a platform that rides along the power lines. | 2014-01-09 |
20140010955 | METHOD OF PRODUCING ALPHA-FE/R2TM14B-TYPE NANOCOMPOSITE MAGNET - There is provided a method of producing an α-Fe/R | 2014-01-09 |